Drug Information

Drug General Information
Drug ID
D07MPL
Former ID
DCL000231
Drug Name
SNX-5422
Drug Type
Small molecular drug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1/2 [548569]
Hematological malignancies [ICD9: 200-209; ICD10:C81-C86] Phase 1 [548569]
Company
Serenex
Structure
Download
2D MOL

3D MOL
Formula
C25H30F3N5O4
Canonical SMILES
CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4<br />)OC(=O)CN)C(F)(F)F)C
InChI
1S/C25H30F3N5O4/c1-24(2)10-18-21(19(34)11-24)22(25(26,27)28)32-33(18)14-5-8-16(23(30)36)17(9-14)31-13-3-6-15(7-4-13)37-20(35)12-29/h5,8-9,13,15,31H,3-4,6-7,10-12,29H2,1-2H3,(H2,30,36)
InChIKey
AVDSOVJPJZVBTC-UHFFFAOYSA-N
PubChem Compound ID
44195571
Target and Pathway
Target(s) Heat shock protein HSP 90 Target Info Inhibitor [536786], [536899]
KEGG Pathway Protein processing in endoplasmic reticulum
PI3K-Akt signaling pathway
Antigen processing and presentation
NOD-like receptor signaling pathway
Progesterone-mediated oocyte maturation
Estrogen signaling pathway
Pathways in cancer
Prostate cancer
NetPath Pathway IL2 Signaling Pathway
TCR Signaling Pathway
Pathway Interaction Database Signaling events mediated by HDAC Class II
Validated targets of C-MYC transcriptional activation
Integrin-linked kinase signaling
LKB1 signaling events
Regulation of Telomerase
Glucocorticoid receptor regulatory network
Class I PI3K signaling events
IL2 signaling events mediated by PI3K
Regulation of Androgen receptor activity
Integrins in angiogenesis
Hypoxic and oxygen homeostasis regulation of HIF-1-alpha
ErbB receptor signaling network
VEGFR1 specific signals
Signaling events mediated by VEGFR1 and VEGFR2
Class I PI3K signaling events mediated by Akt
Reactome Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
Regulation of actin dynamics for phagocytic cup formation
eNOS activation
Regulation of PLK1 Activity at G2/M Transition
Attenuation phase
HSF1-dependent transactivation
Loss of Nlp from mitotic centrosomes
Recruitment of mitotic centrosome proteins and complexes
Loss of proteins required for interphase microtubule organization?from the centrosome
EPHA-mediated growth cone collapse
VEGFA-VEGFR2 Pathway
VEGFR2 mediated vascular permeability
Anchoring of the basal body to the plasma membrane
Constitutive Signaling by EGFRvIII
WikiPathways NRF2 pathway
Nuclear Receptors Meta-Pathway
Aryl Hydrocarbon Receptor Pathway
Binding and Uptake of Ligands by Scavenger Receptors
Signaling by ERBB2
Fcgamma receptor (FCGR) dependent phagocytosis
Influenza Life Cycle
EBV LMP1 signaling
Aryl Hydrocarbon Receptor
Corticotropin-releasing hormone
TNF alpha Signaling Pathway
Arylhydrocarbon receptor (AhR) signaling pathway
Signaling by EGFR
Semaphorin interactions
Mitotic G2-G2/M phases
Metabolism of nitric oxide
NOD pathway
References
Ref 548569Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026704)
Ref 536786Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol. 2008 Aug;8(4):370-4. Epub 2008 Jul 31.
Ref 536899SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood. 2009 Jan 22;113(4):846-55. Epub 2008 Oct 23.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.